Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a low five-year survival rate, yet new immunotherapeutic modalities may offer hope for this and other intractable cancers. Here we report that inhibitory targeting of PI3Kγ, a key macrophage lipid kinase, stimulates anti-tumor immune responses, leading to improved survival and responsiveness to standard-of-care chemotherapy in animal models of PDAC. PI3Kγ selectively drives immunosuppressive transcriptional programming in macrophages that inhibits adaptive immune responses and promotes tumor cell invasion and desmoplasia in PDAC. Blockade of PI3Kγ in PDAC-bearing mice reprograms tumor-associated macrophages to stimulate CD8+ T cell-mediated tumor suppression and to inhibit tumor cell invasion, metastasis and desmoplasia. These data indicate the central role that macrophage PI3Kγ plays in PDAC progression and demonstrate that pharmacological inhibition of PI3Kγ represents a new therapeutic modality for this devastating tumor type.

Targeting CXCR4-dependent immunosuppressive Ly6C low monocytes improves antiangiogenic therapy in colorectal cancer

“…Therefore, there is an urgent need to identify intrinsic and/or acquired immunosuppression mechanisms causing resistance to ICBs and to develop novel immunotherapeutic strategies targeting such resistance mechanisms. There is mounting evidence showing that innate immune cells are actively involved in the development and progression of many types of cancers, albeit with different functions in each cancer (4,5,(46)(47)(48)(49)(50). These innate immune cells are also known to play a critical role in resistance to anti-VEGF therapy in some types of cancers (2, 4).…”

Prognostic Impact of CD163+ Macrophages in Tumor Stroma and CD8+ T-Cells in Cancer Cell Nests in Invasive Extrahepatic Bile Duct Cancer

“…In the current study, adjuvant chemotherapy improved OS in patients with EHBC and this effect was promoted in patients with CD8 Hi CD163 Lo status. A recent study discovered that the inhibition of macrophage phosphoinositide 3 kinase gamma reprogrammed M2-like protumoral macrophages to stimulate CD8 + T cell-mediated suppression of pancreatic cancer and improve the responsiveness to chemotherapy (29). Clinical trials of standard chemotherapy including adjuvant therapy in patients with EHBC are ongoing, but additional therapy to modulate these immune responses could also be really promising.…”

Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer

“…As macrophages including TAMs are plastic, M2-like macrophages can be converted to an M1-like phenotype (21)(22)(23), which is associated with extended survival in patients (24)(25)(26)(27). Innate immune stimulators, including TLR agonists, are under active investigation in the treatment of solid tumors (28)(29)(30)(31).…”